行情

RIGL

RIGL

里格尔制药
NASDAQ

实时行情|Nasdaq Last Sale

2.240
-0.110
-4.68%
盘后: 2.240 0 0.00% 16:06 11/21 EST
开盘
2.360
昨收
2.350
最高
2.366
最低
2.210
成交量
175.75万
成交额
--
52周最高
3.160
52周最低
1.560
市值
3.75亿
市盈率(TTM)
-8.0663
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RIGL 新闻

  • Rigel Pharmaceuticals: Still Underfollowed And Trading At A Discount
  • Seeking Alpha - Article.8小时前
  • Edited Transcript of RIGL earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2天前
  • Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
  • Zacks.3天前
  • Rigel Reports Positive CHMP Opinion For Fostamatinib Disodium Hexahydrate For Adult Patients With Chronic Immune Thrombocytopenia In Europe
  • Benzinga.6天前

更多

所属板块

生物技术和医学研究
-0.31%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

RIGL 简况

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
展开

Webull提供Rigel Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。